Biomarkers to the rescue in a lung nodule epidemic

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 725-726

  Massion, Pierre P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ANXIETY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEST TUBE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EDITORIAL; EPIDEMIC; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; HIGH RISK PATIENT; HUMAN; INCIDENTAL FINDING; LUNG CANCER; LUNG NODULE; PNEUMOTHORAX; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; BLOOD; FEMALE; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; LUNG TUMOR; MALE; MASS SCREENING; METHODOLOGY; NOTE; RADIOGRAPHY;

FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MICRORNAS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84899622435     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.0047     Document Type: Editorial

References (14)

1. Sozzi G, Boeri M, Rossi M, et al: Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. J Clin Oncol 32:768-773, 2014
2. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409, 2011
3. Wiener RS, Schwartz LM, Woloshin S, et al: Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: An analysis of discharge records. Ann Intern Med 155:137-144, 2011
4. Boeri M, Verri C, Conte D, et al: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108:3713-3718, 2011
5. Ventura A, Jacks T: MicroRNAs and cancer: Short RNAs go a long way. Cell 136:586-591, 2009
6. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513-10518, 2008
7. Pritchard CC, Kroh E, Wood B, et al: Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:492-497, 2012
8. Koberle V, Pleli T, Schmithals C, et al: Differential stability of cell-free circulating microRNAs: Implications for their utilization as biomarkers. PLoS One 8:e75184, 2013
9. Bossuyt PM, Reitsma JB, Bruns DE, et al: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 138:40-44, 2003 (Pubitemid 36232093)
10. von Elm E, Altman DG, Egger M, et al: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med 4:e296, 2007
11. Hendriksen JM, Geersing GJ, Moons KG, et al: Diagnostic and prognostic prediction models. J Thromb Haemost 11:129-141, 2013 (suppl 1)
12. Moons KG: Criteria for scientific evaluation of novel markers: A perspective. Clin Chem 56:537-541, 2010
13. Cook NR: Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928-935, 2007
14. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172; discussion 207-212, 2008